Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Relation of C-kit Expression and Dual Esterase Activity to Fish Ph+ Positivity in Patients with CML (CROSBI ID 511496)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Sučić, Mirna ; Davidović-Mrsić, Sanja ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov-Kuveždić, Koraljka ; Vrbanus, Ljiljana ; Zadro, Renata ; Batinić, Drago ; Dubravčić, Klara ; Juričević, Mirjana et al. Relation of C-kit Expression and Dual Esterase Activity to Fish Ph+ Positivity in Patients with CML // The fourth European-American School in forensic genetics and Mayo clinic course in advanced molecular and cellular medicine : Abstracts. Zagreb, 2005. str. 152-152

Podaci o odgovornosti

Sučić, Mirna ; Davidović-Mrsić, Sanja ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov-Kuveždić, Koraljka ; Vrbanus, Ljiljana ; Zadro, Renata ; Batinić, Drago ; Dubravčić, Klara ; Juričević, Mirjana ; Labar, Boris

engleski

Relation of C-kit Expression and Dual Esterase Activity to Fish Ph+ Positivity in Patients with CML

Chronic myelogenous leukemia (CML) is a myeloproliferative disease with t(9 ; 22) and/or BCR/ABL fusion gene. Treatment of CML patients with imatinib mesylate (Gleevec) is based on the inhibition of BCR/ABL and c-kit (CD117) tyrosine kinase activity. The aim of the study was to analyze immunocytochemical expression of CD117 expression and cytochemical dual esterase activity in bone marrow hematopoietic cells (HCs) of CML patients on Gleevec therapy and compare the results with FISH Ph+ positivity. Immunocytochemical APAAP CD117 expression and cytochemical dual esterase activity in HCs were evaluated in 22 patients with CML on Gleveec therapy and in 10 patients without hematological disease (control group). Medians and ranges of CD117+ and dual esterase+ HCs were similar in patients with CML and the control group and without statistical difference. Although medians of CD117+ and FISH Ph+ HCs were highest in CML patients during the first 6 months of Gleveec treatment, correlation of these two parameters was low. FISH Ph+ HCs were significantly lower in CML patients with longer Gleevec therapy. CD117+ HCs were significantly higher in patients with abnormal peripheral blood leukocyte findings. In conclusion, results indicated that Ph+ HCs declined in majority of CML patients on Gleevec therapy. Also, slightly increased CD117+ HCs in CML patients could be connected to inferior response to Gleevec.

chronic myelogenous leukemia; gleevec; c-kit

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

152-152.

2005.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

The fourth European-American School in forensic genetics and Mayo clinic course in advanced molecular and cellular medicine : Abstracts

Zagreb:

Podaci o skupu

European-American school in forensic genetics and Mayo Clinic course in advanced molecular and cellular medicine (4 ; 2005)

poster

05.09.2005-09.09.2005

Dubrovnik, Hrvatska

Povezanost rada

Temeljne medicinske znanosti